MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr. Sharmin Ghaznavi.
Recent Wall Street...
Valhalla Ventures backs visionary founders at the forefront of social and technological movements that younger generations care about most.
The Psychedelic Renaissance is roaring. Over the past...
News Channel 5 Nashville. Ketamine infusions are being used to treat patients with severe depression. The medicine is also a treatment for curb substance abuse addictions.
Pasithea Therapeutics recently raised $24 million at its initial public offering (“IPO”). The Company’s Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the...
"I believe that we are on the verge of curing, as opposed to simply treating, certain psychiatric maladies." Dr. Jeffrey Kamlet, Chief Medical Officer of Ehave.
The KCSA Psychedelics Conference features live presentations and speakers who will address the various investment opportunities in psychedelic treatments for mental health disorders.
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
